Modified small interfering rna molecules and methods of use

ABSTRACT

The present invention provides double-stranded RNA molecules that mediate RNA interference in target cells, preferably hepatic cells. The invention also provides double-stranded RNA (dsRNA) molecules that are modified to be resistant to nuclease degradation, which inactivates a virus, and more specifically, hepatitis C virus (HCV). The invention also provides a method of using these modified RNA molecules to inactivate virus in mammalian cells and a method of making modified small interfering RNAs (siRNAs) using human Dicer. The invention provides modified RNA molecules that are modified to include a dsRNA or siRNA wherein one or more of the pyrimidines in the RNA molecule are modified to include 2′-Fluorine. The invention also provides dsRNA or siRNA in which all pyrimidines are modified to include a 2′-Fluorine. The invention provides that the 2′-Fluorine dsRNA or siRNA molecule is further modified to include a two base deoxynucleotide “TT” sequence at the 3′ end of the molecule.

BACKGROUND OF THE INVENTION

The present invention relates to the field of nucleic acid detection andto the phenomenon of RNA silencing, or RNA interference (RNAi). RNAsilencing constitutes a phenomenon wherein non-coding RNA moleculesmediate specific gene suppression in an organism. In nature, thephenomenon protects an organism's genome from foreign, invading nucleicacids such as transposons, trangenes and viral genes.

The introduction of double-stranded RNA (dsRNA) into a cell triggers RNAsilencing, which then degrades endogenous mRNA corresponding to thedsRNA. RNA silencing pathways involve a conversion of dsRNA into shortinterfering RNAs (siRNAs) that direct ribonucleases to homologous mRNAtargets (Baulcombe et al., 2001). An enzyme called Dicer processes thedsRNA into siRNAs, which are 20-25 nucleotides long. The siRNAs thenassemble into endoribonuclease-containing complexes known as RNA-inducedsilencing complexes (RISCs). Subsequently, the siRNAs guide the RISCs tocomplementary RNA molecules, where the RISCs cleave and destroy thetarget mRNA. Small amounts of dsRNA can silence a large amount of targetmRNA due to an amplification component of RNA silencing (Fire et al.,Nature, 391:806-811 (1998)).

The first evidence that dsRNA produces efficient gene silencing throughRNAi came from studies on the nematode Caenorhabditis elegans (Fire etal., Nature, 391:806-811 (1998) and U.S. Pat. No. 6,506,559). Laterstudies in the fruit fly Drosophila melanogaster demonstrated that RNAiis a multi-step mechanism (Elbashir et al., Genes Dev., 15(2): 188-200(2001)).

Although dsRNA can mediate gene-specific interference in mammalian cells(Wianny, F. and Zernicka-Goetz, M., Nature Cell Biol. 2:70-75 (2000)Svoboda, P. et al., Development 17:4147-4156 (2000)), the use of RNAi inmammalian somatic cells is often limited by a triggering ofdsRNA-dependent protein kinase (PKR), which inactivates the translationfactor eIF2a, causes a generalized suppression of protein synthesis andoften times causes apoptosis (Gil, J. and Esteban, M., Apoptosis5:107-114 (2000)).

Recently, siRNA of approximately 21 or 22 base pairs in length,corresponding to targeted RNA or DNA sequences, were shown to disruptthe expression of the targeted sequences in mammalian cells (Elbashir,S. M., et al., Nature 411: 494-498 (2001)). However, it is not clearthat all RNA or DNA sequences of a mammalian cell's genome aresusceptible to siRNA. It is also uncertain that every mammalian celltype possesses the necessary machinery for effectuating gene-specificsuppression using siRNA. Further, siRNA is of limited use for at leasttwo reasons: (a) the transient nature of the suppression effect seen incells where the siRNA has been administered, and (b) the necessity forchemical synthesis of siRNAs before their use (Tuschl, T., NatureBiotech., 20: 446-448 (2002)). Also, since siRNAs are unstable in vivo,their long-term effectiveness is limited.

An invention that addresses these challenges will improve the utility ofRNAi for treating human disease at the level of nucleic acid activity.In particular, such an invention will make RNAi a more practical therapyfor viral infections, such as infections with HCV. Current therapies forsuch viral infections are very limited, and tend to have poor responserates.

SUMMARY OF THE INVENTION

In a first embodiment, the invention provides a double-stranded (dsRNA)molecule that mediates RNA interference in target cells wherein one ormore of the pyrimidines in the dsRNA are modified to include a2′-Fluorine.

In a second embodiment, the invention provides a small interfering RNA(siRNA) that mediates RNA interference in target cells wherein one ormore of the pyrimidines in the siRNA are modified to include a2′-Fluorine.

In a third embodiment, all of the pyrimidines in the dsRNA or siRNAmolecules of the first and second embodiments are modified to include a2′-Fluorine.

In a fourth embodiment, the 2′-Fluorine dsRNA or siRNA of the thirdembodiment's further modified to include a two base deoxynucleotide “TT”sequence at the 3′ end of the dsRNA or siRNA.

In a fifth embodiment, the 2′-Fluorine dsRNA or siRNA of the thirdembodiment inhibits viral replication in infected cells.

In a sixth embodiment, the 2′-Fluorine dsRNA or siRNA of the fifthembodiment correspond to hepatitis C virus (HCV) nucleic acids andinhibit replication of HCV in hepatic cells.

In a seventh embodiment, there is provided a method for inactivating avirus in a patient comprising administering to said patient a2′-Fluorine dsRNA or siRNA in an effective amount to inactivate saidvirus.

In an eighth embodiment, there is provided a method for inactivating avirus in a patient comprising administering to said patient a2′-Fluorine dsRNA or siRNA in an effective amount to inactivate saidvirus, wherein all of the pyrimidines in the dsRNA or siRNA are modifiedto include a 2′-Fluorine.

In an ninth embodiment, there is provided a method for inactivating avirus in a patient comprising administering to said patient a2′-Fluorine dsRNA or siRNA in an effective amount to inactivate saidvirus wherein the 2′-Fluorine dsRNA or siRNA is further modified toinclude a two base deoxynucleotide “TT” sequence at the 3′ end of thedsRNA or siRNA.

In a tenth embodiment, there is provided a method for inactivating avirus in a patient comprising administering to said patient a2′-Fluorine dsRNA or siRNA in an effective amount to inactivate saidvirus, wherein said virus is selected from the group consisting ofhepatitis C virus (HCV), hepatitis A virus, hepatitis B virus, hepatitisD virus, hepatitis E virus, Ebola virus, influenza virus, rotavirus,reovirus, retrovirus, poliovirus, human papilloma virus (HPV),metapneumovirus and coronavirus.

In an eleventh embodiment, there is provided a method for inactivating avirus in a patient comprising administering to said patient a2′-Fluorine dsRNA or siRNA in an effective amount to inactivate saidvirus, wherein said virus is HCV.

In a twelfth embodiment, there is provided a method of preparing ansiRNA comprising the steps of:

(a) identifying a target nucleotide sequence in an HCV genome fordesigning a siRNA; and

(b) producing an siRNA that contains at least one pyrimidine in thesiRNA which is modified to include a 2′-Fluorine.

In an thirteenth embodiment, there is provided a method of preparing ansiRNA comprising the steps of:

(a) identifying a target nucleotide sequence in an HCV genome fordesigning a siRNA; and

(b) producing an siRNA wherein all of the pyrimidines in the siRNA aremodified to include a 2′-Fluorine.

In a fourteenth embodiment, there is provided a method of preparing ansiRNA comprising the steps of:

(a) identifying a target nucleotide sequence in an HCV genome fordesigning a siRNA; and

(b) producing an siRNA wherein all of the pyrimidines in the siRNA aremodified to include a 2′-Fluorine and wherein the 2′-Fluorine siRNA isfurther modified to include a two base deoxynucleotide “TT” sequence atthe 3′ end of the dsRNA or siRNA.

In a fifteenth embodiment, wherein said target nucleotide sequence inthe fourteenth embodiment is selected from the group consisting of5′-untranslated region (5′-UTR), 3′-untranslated region (3′-UTR), core,and NS3 helicase.

In a sixteenth embodiment, there is provided a dsRNA molecule of fromabout 10 to about 30 nucleotides that inhibits replication of HCV,wherein said dsRNA contains at least one pyrimidine in the siRNA whichis modified to include a 2′-Fluorine.

In a seventeenth embodiment, there is provided a dsRNA molecule of fromabout 10 to about 30 nucleotides that inhibits replication of HCV,wherein all of the pyrimidines in the dsRNA are modified to include a2′-Fluorine.

In an eighteenth embodiment, there is provided a dsRNA molecule of fromabout 10 to about 30 nucleotides that inhibits replication of HCV,wherein all of the pyrimidines in the dsRNA are modified to include a2′-Fluorine and wherein the 2′-Fluorine dsRNA is further modified toinclude a two base deoxynucleotide “TT” sequence at the 3′ end of thedsRNA.

In a nineteenth embodiment there is provided a method of inducingtargeted RNA interference toward HCV in hepatic cells, comprisingadministering the dsRNA molecule of sixteenth embodiment to hepaticcells and wherein the nucleotide sequence of said dsRNA moleculecorresponds to an HCV nucleotide sequence.

In a twentieth embodiment, there is provided a vector comprising a DNAsegment encoding the dsRNA molecule of the sixteenth embodiment.

In a twenty first embodiment, there is provided a vector comprising aDNA segment encoding the dsRNA molecule of the sixteenth embodimentwherein the sense strand of said double-stranded RNA molecule isoperably linked to a first promoter and wherein the antisense strand ofsaid double-stranded RNA molecule of is operably linked to a secondpromoter.

In a twenty second embodiment, there is provided a host cell comprisingthe vector of the twentieth embodiment.

In a twenty third embodiment, the invention provides a method for thedelivery of siRNA to hepatocytes in an animal for therapeutic purposes,including inactivating a virus in the animal. The method comprisesadministering a cholesterol-lowering drug to an animal in conjunctionwith the administration of a dsRNA or siRNA that is modified to furthercomprise a cholesterol as a receptor-binding ligand (cholesterol-siRNA).The cholesterol-lowering drug can be administered prior to, at the sametime, or subsequent to the administration of the cholesterol-labeledsiRNA. In one preferred embodiment, the cholesterol lowering drug is astatin.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 depicts the sequence and secondary structure of the 5′ UTR fromthe HCV genome (SEQ ID NO: 2). It also provides specific sequences ofsiRNAs for inducing RNAi toward HCV in hepatic cells (SEQ ID NOS 3-10,respectively in order of appearance).

FIG. 2 provides sequences for several HCV-specific siRNAs that areuseful for inducing RNAi toward HCV in hepatic cells. Each HCV-specificsiRNA is identified by the designation provided in the first column. Thesequences shown on the left are SEQ ID NOS 11-29 and the sequences shownon the right are SEQ ID NOS 30-67, respectively in order of appearance.

FIG. 3 shows the nucleotide sequence of the SARS coronavirus (SEQ ID NO:1).

FIG. 4 is a schematic representation of the open reading frames of theSARS coronavirus (bases 27263-27272 of SEQ ID NO: 1 are shown).

FIG. 5 depicts a subgenomic HCV replicon contained in the hepatoma cellline Huh 7, which was used to test the efficacy of siRNA in human livercells.

FIG. 6 depicts the dose response of normalized luciferase activity inHuh-7 cells containing the subgenomic HCV replicon (5-2 line), that wereadministered different concentrations of siRNA5. Luciferase activity,which was measured at 1, 2 and 3 days post-transfection, fell withincreasing doses of siRNA. The luciferase assay was performed using aLuciferase assay system available from Promega Corp. (Madison, Wis.),according to the manufacturer's instructions.

FIG. 7 depicts the sequence specificity of siRNA5 for inducingHCV-directed RNAi in Huh-7 liver cells.

FIG. 8 demonstrates that siRNA5 is not toxic to Huh-7 cells. ATPaselevels were assayed using an ATPase assay kit available from PromegaCorp. (Madison, Wis.), according to the manufacturer's instructions.

FIG. 9 depicts the effects of siRNA5 on HCV replication in 21-5 cells(Huh-7 cells containing full-length HCV), as measured by RNA assay. RNAlevels were assayed using a TaqMan™ RNA kit (F. Hoffman La-Roche,Switzerland), according to the manufacturer's instructions. Values arenormalized.

FIG. 10 demonstrates that siRNA5 does not affect the viability of Huh5-2 cells. Specifically, mRNA encoding GAPDH, an enzyme essential toglycolysis was measured in Huh 5-2 cells transfected with siRNA5 orGAPDH-specific siRNA. The graph demonstrates that siRNA5 did not affectRNA levels of GAPDH. GAPDH was measured using a TaqMan™ RNA kit (F.Hoffman La-Roche, Switzerland), according to the manufacturer'sinstructions. Values are normalized.

FIG. 11 depicts a dose response of normalized luciferase activity in Huh7 cells containing a subgenomic HCV replicon (5-2 line) that wereadministered different concentrations of 2′-fluoro-siRNA (2′-F-GL2),which targets the fruit fly luciferase gene. Luciferase activity, whichwas measured at 2 days post-transfection, fell with increasing doses ofsiRNA. The luciferase assay was performed using a Firefly Luciferase kit(Promega Corp., Madison, Wis.), according to the manufacturer'sinstructions.

FIG. 12 demonstrates an inhibition of luciferase activity in 5-2 cellsusing the siRNA Chol-GL2 in the absence of liposomes.

FIG. 13 depicts an autoradiograph of 5′-labeled siRNA duplexes separatedby PAGE, and shows the stability of 2′-fluoro-modified siRNA (2′-F-GL2)incubated in human serum for up to 10 days. The siRNA duplexes weresubjected to incubation with human serum and analysis by 20% PAGE. Thecomposition of the lanes is as follows: Lanes 1, 11 and 21: ³²P-endlabeled siRNA alone; Lanes 2-10, 12-20 and 22-25: siRNA incubated withhuman serum. Lanes 2 & 12, 1 min; Lanes 3 & 13, 5 min; Lanes 4 & 14, 15min; Lanes 5 & 15, 30 min; Lanes 6 & 16, 1 hr; Lanes 7 & 17, 2 hr; Lanes8 & 18, 4 hr; Lanes 9 & 19, 8 hr; Lanes 10 & 20, 24 hr; Lanes 22, 24 hr;Lanes 23, 48 hr; Lanes 24, 120 hr; Lanes 25, 240 hr incubation,respectively.

FIG. 14 demonstrates the use of recombinant human dicer to convertfluorinated dsRNA into 2′F-siRNA. The composition of the lanes is asfollows: Lane 1: size marker, λ\HindIII+φX174\HaeIII; Lane 2: ribo/ribohomoduplex RNA; Lane 3: ribo/2′-F heteroduplex RNA; Lane 4: 2′-F/riboheteroduplex RNA; Lane 6: size marker, 10 bp DNA ladder; Lane 7:ribo/ribo homoduplex siRNA; Lane 8: ribo/2′-F heteroduplex siRNA; Lane9: 2′-F/ribo heteroduplex siRNA; Lane 10: 2′-F12′-F homoduplex siRNA.

FIG. 15 shows a dose response of normalized luciferase activity in Huh-7cells containing the subgenomic HCV replicon (5-2 line) to HCV-specificsiRNAs. Luciferase activity fell with increasing doses of each siRNA.

FIG. 16 shows that cholesterol shows a dose response of normalizedluciferase activity in Huh-7 cells containing the subgenomic HCVreplicon (5-2 line) to cholesterol-modified GL2 siRNA.

FIG. 17 demonstrates the increased stability seen with an siRNA that hasbeen modified to include 2-Fluoro pyrimidines replacing all of thepyrimidines (2-F-siRNA) and 2-Fluoro pyrimidines replacing all of thepyrimidines and also a two base deoxynucleotide “TT” sequence added tothe 3′ends of the molecule in place of the ribonucleotide “UU” overhangspresent in 2-F-siRNA (2′-F-siRNA 3′-X).

FIG. 18 shows that siRNA stability can be dramatically increased byfluorination within 2′-sugar.

FIG. 19 shows evaluation of siRNA in vivo.

FIG. 20 shows conjugated 2′-F-siRNA is efficacious in chimeric mice bylow pressure IV injection.

FIG. 21 shows conjugated 2′-F-siRNA given subcutaneously is partiallyeffective in chimeric mice.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides dsRNA molecules that are about 10 toabout 30 nucleotides long, and that mediate RNA interference in targetcells. Preferably, the inventive molecules are chemically modified toconfer increased stability against nuclease degradation, but retain theability to bind to target nucleic acids.

As used herein, “RNA interference” (RNAi) refers to sequence-specific orgene specific suppression of gene expression (protein synthesis) that ismediated by siRNA, without generalized suppression of protein synthesis.While the invention is not limited to a particular theory or mode ofaction, RNAi may involve degradation of messenger RNA (mRNA) by anRNA-induced silencing complex (RISC), preventing translation of thetranscribed mRNA. Alternatively, it may involve methylation of genomicDNA, which shunts transcription of a gene. The suppression of geneexpression caused by RNAi may be transient or it may be more stable,even permanent.

“Gene suppression”, “targeted suppression”, “sequence-specificsuppression”, “targeted RNAi” and “sequence-specific RNAi” are usedinterchangeably herein. Furthermore, sequence-specific suppression, asused herein, is determined by separately assaying levels of the proteintargeted for suppression in cells containing the siRNA (experimentalcells) and in cells not containing the identical siRNA (control cells),then comparing the two values. Experimental and control cells should bederived from the same source and same animal. Also, control andexperimental cells used in determining the level or quantity of genesuppression should be assayed under similar, if not identical,conditions.

RNA is a polymer of ribonucleotides, each containing the sugar ribose inassociation with a phosphate group and a nitrogenous base (typically,adenine, guanine, cytosine, or uracil). Like its cousin, DNA, RNA canform complementary hydrogen bonds. Therefore, RNA may be double-stranded(dsRNA), single-stranded (ssRNA) or double-stranded with asingle-stranded overhang. Common types of RNA include messenger RNA(mRNA), transfer RNA (tRNA), ribosomal RNA (rRNA), short interfering RNA(siRNA), micro RNA (miRNA) and small hairpin RNA (shRNA), each of whichplays a specific role in biological cells. As used herein, the term“RNA” includes all of these.

“Small interfering RNA” (siRNA) refers to double-stranded RNA moleculesfrom about 10 to about 30 nucleotides long that are named for theirability to specifically interfere with protein expression. Preferably,siRNA molecules are 12-28 nucleotides long, more preferably 15-25nucleotides long, still more preferably 19-23 nucleotides long and mostpreferably 21-23 nucleotides long. Therefore, preferred siRNA moleculesare 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27 28 or29 nucleotides in length.

The length of one strand designates the length of an siRNA molecule. Forinstance, an siRNA that is described as 21 ribonucleotides long (a21-mer) could comprise two opposite strands of RNA that anneal togetherfor 19 contiguous base pairings. The two remaining ribonucleotides oneach strand would form an “overhang.” When an siRNA contains two strandsof different lengths, the longer of the strands designates the length ofthe siRNA. For instance, a dsRNA containing one strand that is 21nucleotides long and a second strand that is 20 nucleotides long,constitutes a 21-mer.

siRNAs that comprise an overhang are desirable. The overhang may be atthe 5′ or the 3′ end of a strand. Preferably, it is at the 3′ end of theRNA strand. The length of an overhang may vary, but preferably is about1 to about 5 bases, and more preferably is about 2 nucleotides long.Preferably, the siRNA of the present invention will comprise a 3′overhang of about 2 to 4 bases. More preferably, the 3′ overhang is 2ribonucleotides long. Even more preferably, the 2 ribonucleotidescomprising the 3′ overhang are uridine (U).

siRNAs of the present invention are designed to interact with a targetribonucleotide sequence, meaning they complement a target sequencesufficiently to bind to the target sequence. Preferably the targetribonucleotide sequence derives from a disease producing agent orpathogen. More preferably, the target ribonucleotide sequence is in avirus genome of an RNA virus or a DNA virus. Even more preferably, thevirus is selected from the group consisting of hepatitis C virus (HCV),hepatitis A virus, hepatitis B virus, hepatitis D virus, hepatitis Evirus, Ebola virus, influenza virus, rotavirus, reovirus, retrovirus,poliovirus, human papilloma virus (HPV), metapneumovirus andcoronavirus.

Hepatitis C virus (HCV) is a highly preferred virus target. FIG. 1 andFIG. 2 disclose the nucleic acid sequences for several HCV-specificsiRNA molecules. Among those shown, siRNA5, siRNAC1, siRNAC2, siRNA5B1,siRNA5B2, and siRNA5B4 have shown particularly good activity, andtherefore are highly preferred. siRNAs at least 80%, 90%, or 95%,identical to these highly preferred siRNAs also constitute part of theinvention.

Another preferred virus target is the coronavirus, which is associatedwith upper respiratory infections in humans and recently has been linkedwith SARS (severe acute respiratory syndrome). Coronavirus has thelargest known RNA virus genome, 32 kilobases long, and its genome iscomposed of positively stranded RNA. (See FIG. 5) Each coronavirus mRNAhas a 5′-end leader sequence of 60 to 80 nucleotides that is identicalto the 5′-UTR of genomic RNA approximately 200 nucleotides long. (SeeFIG. 6) These sequences are highly conserved, and therefore, provide anexcellent source of target sequences for which siRNAs. See FundamentalVirology, 3^(rd) Ed., Chapter 18, p. 541-560 (Eds. Fields, Knipe andHowley), Lippincott-Raven (1995). In one embodiment, the entire leadersequence (nucleotides 1-72) is targeted. In another embodiment, one ormore sections of the leader sequence is targeted. In a preferredembodiment, nucleotides 64-72 (TAAACGAAC) of the leader sequence aretargeted. siRNA targeted to the coronavirus may be modified orunmodified.

In one embodiment, the invention provides an siRNA molecule comprising aribonucleotide sequence at least 80% identical to a ribonucleotidesequence from a target agent or virus. Preferably, the siRNA molecule isat least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to theribonucleotide sequence of the target agent or virus. The target can bethe entire viral genome, a primary transcript, an open reading frame, orany portion of these. Most preferably, an siRNA will be 100% identicalto the nucleotide sequence of a target agent or virus. However, siRNAmolecules with insertions, deletions or single point mutations relativeto a target may also be effective. Tools to assist siRNA design arereadily available to the public. For example, a computer-based siRNAdesign tool is available on the internet at www.dharmacon.com.

By way of example, a polynucleotide having a nucleotide sequence atleast 95% “identical” to a reference nucleotide sequence means that thepolynucleotide's sequence may include up to five point mutations per 100nucleotides of the reference nucleotide sequence, or 1 point mutationper 20 nucleotides. In other words, to obtain a polynucleotide having anucleotide sequence at least 95% identical to a reference nucleotidesequence, up to 5% of the nucleotides in the reference sequence may bedeleted or substituted with another nucleotide, or a number ofnucleotides up to 5% of the total nucleotides in the reference sequencemay be inserted into the reference sequence. These mutations of thereference sequence may occur at the 5′ or 3′ terminal positions of thereference nucleotide sequence or anywhere between those terminalpositions, interspersed either individually among nucleotides in thereference sequence or in one or more contiguous groups within thereference sequence.

As a practical matter, whether any particular nucleic acid molecule isat least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to theribonucleotide sequence of a target agent or virus can be determinedconventionally using known computer programs such as the Bestfit program(Wisconsin Sequence Analysis Package, Version 8 for Unix, GeneticsComputer Group, Madison, Wis.). Bestfit uses the local homologyalgorithm of Smith and Waterman (Advances in Applied Mathematics2:482-489 (1981)) to find the best segment of homology between twosequences. When using Bestfit or any other sequence alignment program todetermine whether a particular sequence is, for instance, 95% identicalto a reference sequence according to the present invention, theparameters are set, of course, such that the percentage of identity iscalculated over the full length of the reference ribonucleotide sequenceand that gaps in homology of up to 5% of the total number ofribonucleotides in the reference sequence are allowed.

The present invention also includes siRNA molecules that have beenchemically modified to confer increased stability against nucleasedegradation, but retain the ability to bind to target nucleic acids thatmay be present in cells. In the case where a target RNA isvirus-specific, the modified siRNAs are able to bind to the virusspecific RNAs or DNAs, thereby inactivating the virus.

A modified siRNA of the present invention comprises a modifiedribonucleotide, and is resistant to enzymatic degradation, such as RNasedegradation, yet retains the ability to inhibit viral replication in acell containing the specific viral target RNA or DNA sequences. ThesiRNA may be modified at any position of the molecule so long as themodified siRNA binds to a target sequence and is resistant to enzymaticdegradation. Modifications in the siRNA may be in the nucleotide base,i.e., the purine or the pyrimidine, the ribose or the phosphate.Preferably, the modification occurs at the 2′ position of at least oneribose in an siRNA.

More specifically, the siRNA is modified in at least one pyrimidine, atleast one purine or a combination thereof. However, generally allpyrimidines (cytosine or uracil), or all purines (adenosine or guanine)or a combination of all pyrimidines and all purines of the siRNA aremodified. More preferably, the pyrimidines are modified, and thesepyrimidines are cytosine, a derivative of cytosine, uracil, a derivativeof uracil or a combination thereof. Ribonucleotides on either one orboth strands of the siRNA may be modified.

Ribonucleotides containing pyrimidine bases found in RNA (cytidine anduridine) can be chemically modified by adding any molecule that inhibitsRNA degradation or breakdown of the base, the ribose or the phosphates.As previously noted, the 2′ position of ribose is a preferred site formodification. 2′ modified siRNAs have a longer serum half-life and areresistant to degradation, relative to unmodified siRNAs orsingle-stranded RNAs, such as antisense or ribozyme. 2′-modifiedpyrimidine ribonucleotides can be formed by a number of differentmethods known in the art.

A preferable chemical modification is the addition of a molecule fromthe halide chemical group to a ribonucleotide of siRNA. Within thehalides, fluorine is a preferred molecule. Besides fluoro-, otherchemical moieties such as methyl-, methoxyethyl- and propyl- may beadded as modifications. The most preferred modification, though, isfluoro-modification, such as a 2′-fluoro-modification or a2′,2′-fluoro-modification.

Thus, in a preferred embodiment of the invention, siRNA is modified bythe addition of a fluorine molecule to the 2′ carbon of a pyrimidineribonucleotide. The siRNA may be fluorinated completely or partially.For example, only the cytosine ribonucleotides may be fluorinated.Alternatively, only the uracil ribonucleotides may be fluorinated. In apreferred embodiment, both uracil and cytosine are fluorinated. Only onestrand, either sense or antisense, of siRNA may to be fluorinated. Evenpartial 2′ fluorination of siRNA gives protection against nucleolyticdegradation. Importantly, 2′ fluorinated siRNA is not toxic to cells, anunexpected result given that fluorine chemistry usually is toxic toliving organisms.

In addition, modified siRNAs of the present invention may containchemical modifications that inhibit viral RNA polymerases. For example,siRNAs may comprise one or more nucleosides that inhibit viralRNA-dependent RNA polymerases. Examples of such nucleosides and otherchemical modifications exist in WO 02/057425, WO 02/057287, WO 02/18404,WO 02/100415, WO 02/32920, WO 01/90121, U.S. Pat. No. 6,063,628 and USpublished application No. 2002/0019363.

siRNA can be prepared in a number of ways, such as by chemicalsynthesis, T7 polymerase transcription, or by treating long doublestranded RNA (dsRNA) prepared by one of the two previous methods withDicer enzyme. Dicer enzyme creates mixed populations of dsRNA from about21 to about 23 base pairs in length from dsRNA that is about 500 basepairs to about 1000 base pairs in size. Unexpectedly, Dicer caneffectively cleave modified strands of dsRNA, such as 2′ fluoro-modifieddsRNA. Before development of this method, it was previously thought thatDicer would not be able to cleave modified siRNA. The Dicer method ofpreparing siRNAs can be performed using a Dicer siRNA Generation Kitavailable from Gene Therapy Systems (San Diego, Calif.).

The invention particularly includes a method of making a modified siRNAthat targets a nucleic acid sequence in a virus, comprising (a)preparing a modified-double stranded RNA (dsRNA) fragment containing atleast one modified ribonucleotide in at least one strand, and (b)cleaving the modified-dsRNA fragments with recombinant human Dicer,resulting in more than one modified siRNA. The method may furthercomprise (c) isolating the modified siRNAs.

In the methods for making siRNA, a dsRNA fragment can be prepared bychemical synthesis or in vitro translation. In one embodiment, themodified siRNA is a 2′ modified siRNA in which the modification is atthe 2′ position of at least one ribonucleotide of said siRNA. Themodification is selected from the group consisting of fluoro-, methyl-,methoxyethyl and propyl-modification. Preferably the fluoro-modificationis a 2′-fluoro-modification or a 2′,2′-fluoro-modification. Thepyrimidines, the purines or a combination thereof of the siRNA aremodified. More preferably, the pyrimidines are modified, such ascytosine, a derivative of cytosine, uracil, a derivative of uracil or acombination thereof. One or both strands of the siRNA may contain one ormore modified ribonucleotide.

The invention further provides a method of inactivating a target agentor virus in a patient by administering to the patient a dsRNA in aneffective amount to inactivate the targeted agent or virus. Preferablythe dsRNA is modified as described above. RNA interference toward atargeted DNA segment in a cell can be achieved by administering adouble-stranded RNA molecule to the cells, wherein the ribonucleotidesequence of the double-stranded RNA molecule corresponds to theribonucleotide sequence of the targeted DNA segment. Preferably, thedsRNA used to induce targeted RNAi is siRNA.

As used herein “targeted DNA segment” is used to mean a DNA sequenceencoding, in whole or in part, an mRNA for a targeted protein, includingintrons or exons, where suppression is desired. DNA segment can alsomean a DNA sequence that normally regulates expression of the targetedprotein, including but not limited to the promoter of the targetedprotein. Furthermore, the DNA segment may or may not be a part of thecell's genome or it may be extrachromosomal, such as plasmid DNA.

The present invention is particularly directed to a method ofinactivating a virus in a patient by administering to the patient ansiRNA, preferably a modified siRNA, in an effective amount to inactivatethe virus. The siRNA is preferably about 10 to about 30 ribonucleotidesin length, more preferably 12-28 ribonucleotides, more preferably 15-25ribonucleotides, even more preferably 19-23 ribonucleotides and mostpreferably 21-23 ribonucleotides.

Also, the method of inactivating a virus preferably utilizes an siRNAthat is modified at the 2′ position of at least one ribonucleotide ofsaid siRNA. The siRNA may be modified with chemical groups selected fromthe group consisting of fluoro-, methyl-, methoxyethyl- and propyl-.Fluoro-modification is most preferred, and either a2′-fluoro-modification or a 2′,2′-fluoro-modification is useful in themethod. The modification may be at a pyrimidine, a purine or acombination thereof of the siRNA. More preferably the pyrimidines aremodified, such as cytosine, a derivative of cytosine, uracil, aderivative of uracil or a combination thereof. In one embodiment, onestrand of the siRNA contains at least one modified ribonucleotide, whilein another embodiment, both strands of the siRNA contain at least onemodified ribonucleotide.

siRNAs useful in treatment methods may also be modified by theattachment of at least one, but preferably more than one,receptor-binding ligand(s) to the siRNA. Such ligands are useful todirect delivery of siRNA to a target virus in a body system, organ,tissue or cells of a patient, such as the liver, gastrointestinal tract,respiratory tract, the cervix or the skin.

In preferred embodiments, receptor-binding ligands are attached toeither a 5′-end or a 3′-end of an siRNA molecule. Receptor-bindingligands may be attached to one or more siRNA ends, including anycombination of 5′- and 3′-ends. Thus, when receptor binding ligands areattached only to the ends of an siRNA molecule, anywhere between 1 and 4such ligands may be attached.

The selection of an appropriate ligand for targeting siRNAs to virusesin particular body systems, organs, tissues or cells is considered to bewithin the ordinary skill of the art. For example, to target an siRNA tohepatocytes, cholesterol may be attached at one or more ends, includingany combination of 5′- and 3′-ends, of an siRNA molecule. The resultantcholesterol-siRNA is delivered to hepatocytes in the liver, therebyproviding a means to deliver siRNAs to this targeted location. Otherligands useful for targeting siRNAs to the liver include HBV surfaceantigen and low-density lipoprotein (LDL).

As another example, siRNA molecules that target Human Immunodeficiencyvirus type 1 (HIV-1) can be delivered to T lymphocytes where the targetnucleic acids are located (Song, E. et al., J. of Virology, 77(13):7174-7181 (2003)). This delivery can be accomplished by attaching, atthe 3′-end or 5′-end of siRNA molecules, HIV-1 surface antigen capableof binding to the CD4 surface protein located on T-cells (Kilby, M. etal., New England J. of Medicine, 348(22): 2228-38 (2003)).

Similarly, siRNA molecules that target Influenza A virus can bedelivered to epithelial cells of the respiratory tract where the targetnucleic acids are located (Ge, Q. et al., Proc. Natl. Acad. of Sciences,100(5): 2718-2723 (2002)). This delivery can be accomplished byattaching, at the 3′-end or 5′-end of siRNA molecules, the Influenzavirus surface antigen, which is capable of binding to the sialic acidresidues located on the surface of the epithelial cells (Ohuchi, M., etal., J. of Virology, 76(24): 12405-12413 (2002); Glick, G. et al., J. ofBiol. Chem., 266 (35): 23660-23669 (1991)).

Also, siRNA molecules that target respiratory syncitial virus (RSV) canbe delivered to epithelial cells of the respiratory tract where thetarget nucleic acids are located (Bitko, V. et al., BMC Microbiology,1:34 (2001)). This delivery can be accomplished by attaching, at the3′-end or 5′-end of siRNA molecules, RSV surface antigen (Malhotra, R.et al., Microbes and Infection, 5: 123-133 (2003)).

As still another example, siRNAs that target Human Papillomavirus (HPV)can be delivered to basal epithelial cells where the target nucleicacids are located (Hall, A. et al., J. of Virology, 77(10): 6066-6069(2003)). This delivery can be accomplished by attaching, at the 3′-endor 5′-end of siRNA molecules, HPV surface antigen capable of binding toheparin sulfate proteoglycans located on the surface of basal epithelialcells (Bousarghin L. et al., J. of Virology, 77(6): 3846-3850 (2002)).

Further, siRNAs that target Poliovirus (PV) can be delivered to cells ofthe nervous system where the target nucleic acids are located (Gitlin,L. et al., Nature, 418: 430-434 (2002)). This delivery can beaccomplished by attaching, at the 3′-end or 5′-end of siRNA molecules,PV surface antigen capable of binding to the CD155 receptor located onthe surface of neurons (He, Y. et al., Proc. Natl. Acad. of Sciences, 97(1): 79-84 (2000)).

As noted, the methods of treatment are intended to targetdisease-causing agents or pathogens, and more particularly viruses,which can be either RNA viruses or DNA viruses. Preferred viruses areselected from the group consisting of hepatitis C virus (HCV), hepatitisA virus, hepatitis B virus, hepatitis D virus, hepatitis E virus, Ebolavirus, influenza virus, rotavirus, reovirus, retrovirus, poliovirus,human papilloma virus (HPV), metapneumovirus and coronavirus. Morepreferably the target virus is hepatitis C virus or a coronavirus.

In one aspect, the method utilizes an siRNA prepared by (a) identifyinga target ribonucleotide sequence in a virus genome for designing a smallinterfering RNA (siRNA) and (b) producing a siRNA that has been modifiedto contain at least one modified ribonucleotide. Preferably, the siRNAcomprises a double-stranded RNA molecule with a first strandribonucleotide sequence corresponding to a ribonucleotide sequencecorresponding to a target ribonucleotide sequence in the virus, and asecond strand comprising a ribonucleotide sequence complementary to thetarget ribonucleotide sequence. The first and second strands should beseparate complementary strands that hybridize to each other to form adouble-stranded RNA molecule. Moreover, one or both of the strandsshould comprise at least one modified ribonucleotide.

In preferred embodiments of the invention, the siRNA targets aribonucleotide sequence in the hepatitis C virus genome. The targetribonucleotide sequence comprises a conserved ribonucleotide sequencenecessary for HCV replication, and the conserved ribonucleotide sequenceis selected from the group consisting of 5′-untranslated region(5′-UTR), 3′-untranslated region (3′-UTR), core, and NS3 helicase.Highly preferred siRNA molecules comprise a sequence at least 80%identical to those of siRNA5, siRNAC1, siRNAC2, siRNA5B1, siRNA5B2, orsiRNA5B4. The siRNAs may be unmodified, or modified as described above.

Methods of inhibiting the replication of HCV in cells positive for HCVshould not be toxic to the cells, or cause apoptosis in the treatedcells. Preferably, the inhibition of HCV replication is specificallytailored to affect only HCV replication in the cells, such that normalgrowth, division or metabolism is not affected. Cells in which HCV hasbeen shown to replicate include, but are not limited to hepatic cells, Bcell lymphocytes and T cell lymphocytes. Preferably, a method ofinhibiting the replication of HCV is performed in hepatic cells.

According to the invention, “hepatic cells” can be from any animalsource. Further, the hepatic cells may be in cell culture, or part of atissue, or an organ, in part or in whole. The phrase hepatic cells ismeant to include any cell constituting a normal, abnormal or diseasedliver cell. Examples of hepatic cells include, but are not limited to,Kupffer cells, hepatocytes and cells comprising a hepatocellularcarcinoma. “Hepatic cells” is not meant to include cells that make updiscrete structures within the liver, such as endothelial cells liningblood vessels. A tissue or organ containing the hepatic cells may bewithin a subject or may be biopsied or removed from the animal.Additionally, the tissue may be “fresh” in that the tissue would berecently removed from a subject, without any preservation steps betweenthe excision and the methods of the current invention. Prior toapplication of the methods of the current invention, the tissue may alsohave been preserved by such standard tissue preparation techniquesincluding, but not limited to, freezing, quick freezing, paraffinembedding and tissue fixation. Furthermore, the tissue may also be axenograft or a syngraft on or in another host animal. As used herein,the terms animal and subject are used interchangeably.

According to the invention, “hepatitis C virus,” or “HCV,” takes itsordinary meaning in the art as of the date of invention. The hepatitis Cvirus is an RNA virus of the Flaviviridae family. For example as usedherein, HCV includes, but is not limited to genotypes 1-11 (using themost common genotyping system), with these genotypes being broken downinto sub-types, some of which include but are not limited to 1a, 1b, 1c,2a, 2b, 2c, 3a, 3b, 4a, 4b, 4c, 4d, 4e, 5a, 6a, 7a, 7b, 8a, 8b, 9a, 10aand 11a. Further, isolates from individuals consist of closely relatedyet heterogeneous populations of viral genomes, sometimes referred to asquasispecies.

Pestivirus is yet another target of the present invention. As usedherein, “pestivirus” takes its ordinary meaning in the art as of thedate of invention. The pestivirus belongs to the family Flaviviridae.Pestivirus is widespread throughout the Australian cattle population. Itis believed that about 70% of herds are actively infected withpestivirus. Infection of susceptible animals can cause a variety ofdiseases—some not apparent until well after the initial spread of thevirus into a herd. Pestivirus is a genus of viruses that includes hogcholera virus, bovine viral diarrhea virus (BVDV) and border diseasevirus (BDV) or hairy-shaker disease virus.

siRNA may be administered to a patient by intravenous injection,subcutaneous injection, oral delivery, liposome delivery or intranasaldelivery. The siRNA may then accumulate in a target body system, organ,tissue or cell type of the patient.

The present invention also provides a method of inhibiting thereplication of a virus in mammalian cells, comprising transfecting cellsharboring the virus with a vector that directs the expression ofvirus-specific siRNA. In one embodiment, the invention provides a methodof inhibiting the replication of hepatitis C virus (HCV) in cellspositive for HCV, comprising transfecting HCV-positive cells with avector that directs the expression of an HCV-specific siRNA. The cellsmay be evaluated to determine if a marker in the cells has beeninhibited by the siRNA.

Thus, the invention also provides vectors and host cells comprising anucleic acid segment encoding the described siRNAs.

Vectors of the present invention may be employed for producing siRNAs byrecombinant techniques. Thus, for example, a DNA segment encoding ansiRNA may be included in any one of a variety of expression vectors forexpressing any DNA sequence. Such vectors include chromosomal,nonchromosomal and synthetic DNA sequences, e.g., derivatives of SV40;bacterial plasmids; phage DNA; baculovirus; yeast plasmids; vectorsderived from combinations of plasmids and phage DNA, viral DNA such asvaccinia, adenovirus, fowl pox virus, and pseudorabies. However, anyother vector may be used as long as it is replicable and viable in adesired host.

The appropriate DNA segment may be inserted into the vector by a varietyof procedures. In general, the DNA sequence is inserted into anappropriate restriction endonuclease site(s) by procedures known in theart. Such procedures and others are deemed to be within the scope ofthose skilled in the art.

The DNA segment in the expression vector is operatively linked to anappropriate expression control sequence(s) (promoter) to direct siRNAsynthesis. Suitable eukaryotic promoters include the CMV immediate earlypromoter, the HSV thymidine kinase promoter, the early and late SV40promoters, the promoters of retroviral LTRs, such as those of the RousSarcoma Virus (RSV), and metallothionein promoters, such as the mousemetallothionein-I promoter. Preferably the promoters of the presentinvention are from the type III class of RNA polymerase III promoters.More preferably, the promoters are selected from the group consisting ofthe U6 and H1 promoters. The U6 and H1 promoters are both members of thetype III class of RNA polymerase III promoters. The promoters of thepresent invention may also be inducible, in that expression may beturned “on” or “off.” For example, a tetracycline-regulatable systememploying the U6 promoter may be used to control the production ofsiRNA. The expression vector may or may not contain a ribosome bindingsite for translation initiation and a transcription terminator. Thevector may also include appropriate sequences for amplifying expression.

In addition, the expression vectors preferably contain one or moreselectable marker genes to provide a phenotypic trait for selection oftransformed host cells such as dihydrofolate reductase or neomycinresistance for eukaryotic cell culture, or tetracycline or ampicillinresistance.

Generally, recombinant expression vectors will include origins ofreplication and selectable markers permitting transformation of the hostcell, e.g., the ampicillin resistance gene of E. coli and S. cerevisiaeTRP1 gene, and a promoter derived from a highly-expressed gene to directtranscription of a downstream structural sequence. Such promoters can bederived from operons encoding glycolytic enzymes such as3-phosphoglycerate kinase (PGK), a-factor, acid phosphatase, or heatshock proteins, among others. The heterologous structural sequence isassembled in appropriate phase with translation initiation andtermination sequences, and preferably, a leader sequence capable ofdirecting secretion of translated protein into the periplasmic space orextracellular medium. Optionally, the heterologous sequence can encode afusion protein including an N-terminal identification peptide impartingdesired characteristics, e.g., stabilization or simplified purificationof expressed recombinant product.

In one embodiment, the invention provides a vector, wherein the DNAsegment encoding the sense strand of the RNA polynucleotide is operablylinked to a first promoter and where the DNA segment encoding theantisense (opposite) strand of the RNA polynucleotide molecule of isoperably linked to a second promoter. In other words, each strand of theRNA polynucleotide is independently expressed. Furthermore, the promoterdriving expression of each strand can be identical or each one may bedifferent from the other promoter.

In another embodiment, the vector of the current invention may compriseopposing promoters. For example, the vector may comprise two U6promoters on either side of the DNA segment encoding the sense strand ofthe RNA polynucleotide and placed in opposing orientations, with orwithout a transcription terminator placed between the two opposingpromoters. The U6 opposing promoter construct is similar to the T7opposing promoter construct as described in Wang, Z. et al., J. Biol.Chem. 275: 40174-40179 (2000). See Miyagishi, M. and Taira, K., NatureBiotech. 20: 497-500 (2002).

In another embodiment, the DNA segments encoding both strands of the RNApolynucleotide are under the control of a single promoter. In oneembodiment, the DNA segments encoding each strand are arranged on thevector with a “loop” region interspersed between the two DNA segments,where transcription f the DNA segments and loop region creates one RNAtranscript. The single transcript will, in turn, anneal to itselfcreating a “hairpin” RNA structure capable of inducing RNAi. The “loop”of the hairpin structure is preferably from about 4 to about 6nucleotides in length. More preferably, the loop is 4 nucleotides inlength.

The vector containing the appropriate DNA sequence as described herein,as well as an appropriate promoter or control sequence, may be employedto transform an appropriate host to permit the host to express thesiRNA. Appropriate cloning and expression vectors for use withprokaryotic and eukaryotic hosts are described by Sambrook, et al.,Molecular Cloning: A Laboratory Manual, Second Edition, Cold SpringHarbor, N.Y. (1989), the disclosure of which is hereby incorporated byreference.

Host cells are genetically engineered (transduced or transformed ortransfected) with the vectors of this invention which may be, forexample, cloning vectors or expression vectors. The vectors may be, forexample, in the form of a plasmid, a viral particle, a phage, etc. Theengineered host cells may be cultured in conventional nutrient mediamodified as appropriate for activating promoters, selectingtransformants. The culture conditions, such as temperature, pH and thelike, are those previously used with the host cell selected forexpression, and will be apparent to the ordinarily skilled artisan.

In a further embodiment, the present invention relates to host cellscontaining the above-described constructs. A host cell may be a highereukaryotic cell, such as a mammalian cell, or a lower eukaryotic cell,such as a yeast cell, or the host cell may be a prokaryotic cell, suchas a bacterial cell. Preferably, host cells are mammalian cells. Morepreferably, host cells are hepatic cells. Introduction of a constructinto host cells can be effected by calcium phosphate transfection,DEAE-Dextran mediated transfection, or electroporation (Davis, L., etal., Basic Methods in Molecular Biology (1986)).

The term patient, as used herein, refers to an animal, preferably amammal. More preferably the patient can be a primate, includingnon-human and humans. The terms subject and patient are usedinterchangeably herein.

The treatments envisioned by the current invention can be used forsubjects with a pre-existing viral infection, or for subjectspre-disposed to an infection. Additionally, the methods of the currentinvention can be used to correct or compensate for cellular orphysiological abnormalities involved in conferring susceptibility toviral infections in patients, and/or to alleviate symptoms of a viralinfections in patients, or as a preventative measure in patients.

The method of treating a patient having a viral infection involvesadministration of compositions to the subjects. As used herein,composition can mean a pure compound, agent or substance or a mixture oftwo or more compounds, agents or substances. As used herein, the termagent, substance or compound is intended to mean a protein, nucleicacid, carbohydrate, lipid, polymer or a small molecule, such as a drug.

In one embodiment of the current invention, the composition administeredto the subject is a pharmaceutical composition. Further, thepharmaceutical composition can be administered orally, nasally,parenterally, intrasystemically, intraperitoneally, topically (as bydrops or transdermal patch), bucally, or as an oral or nasal spray.Intranasal delivery of a virus that causes upper respiratory diseases,such as the coronavirus or the metapneumovirus, would be a particularlyadvantageous delivery mode. The term “parenteral,” as used herein,refers to modes of administration that include intravenous,intramuscular, intraperitoneal, intrasternal, subcutaneous andintraarticular injection and infusion. The pharmaceutical compositionsas contemplated by the current invention may also include apharmaceutically acceptable carrier.

“Pharmaceutically acceptable carrier” includes, but is not limited to, anon-toxic solid, semisolid or liquid filler, diluent, encapsulatingmaterial or formulation auxiliary of any type, such as liposomes.

A pharmaceutical composition of the present invention for parenteralinjection can comprise pharmaceutically acceptable sterile aqueous ornonaqueous solutions, dispersions, suspensions or emulsions as well assterile powders for reconstitution into sterile injectable solutions ordispersions just prior to use. Examples of suitable aqueous andnonaqueous carriers, diluents, solvents or vehicles include water,ethanol, polyols (such as glycerol, propylene glycol, polyethyleneglycol, and the like), carboxymethylcellulose and suitable mixturesthereof, vegetable oils (such as olive oil), and injectable organicesters such as ethyl oleate. Proper fluidity can be maintained, forexample, by the use of coating materials such as lecithin, by themaintenance of the required particle size in the case of dispersions,and by the use of surfactants.

The compositions of the present invention can also contain adjuvantssuch as, but not limited to, preservatives, wetting agents, emulsifyingagents, and dispersing agents. Prevention of the action ofmicroorganisms can be ensured by the inclusion of various antibacterialand antifungal agents, for example, paraben, chlorobutanol, phenol, sorbacid, and the like. It can also be desirable to include isotonic agentssuch as sugars, sodium chloride, and the like. Prolonged absorption ofthe injectable pharmaceutical form can be brought about by the inclusionof agents which delay absorption such as aluminum monostearate andgelatin.

In some cases, to prolong the effect of the drugs, it is desirable toslow the absorption from subcutaneous or intramuscular injection. Thiscan be accomplished by the use of a liquid suspension of crystalline oramorphous material with poor water solubility. The rate of absorption ofthe drug then depends upon its rate of dissolution which, in turn, candepend upon crystal size and crystalline form. Alternatively, delayedabsorption of a parenterally administered drug form is accomplished bydissolving or suspending the drug in an oil vehicle.

Injectable depot forms are made by forming microencapsule matrices ofthe drug in biodegradable polymers such as polylactide-polyglycolide.Depending upon the ratio of drug to polymer and the nature of theparticular polymer employed, the rate of drug release can be controlled.Examples of other biodegradable polymers include poly(orthoesters) andpoly(anhydrides). Depot injectable formulations are also prepared byentrapping the drug in liposomes or microemulsions which are compatiblewith body tissues.

The injectable formulations can be sterilized, for example, byfiltration through a bacterial-retaining filter, or by incorporatingsterilizing agents in the form of sterile solid compositions which canbe dissolved or dispersed in sterile water or other sterile injectablemedium just prior to use.

Solid dosage forms for oral administration include, but are not limitedto, capsules, tablets, pills, powders, and granules. In such soliddosage forms, the active compounds are mixed with at least one itempharmaceutically acceptable excipient or carrier such as sodium citrateor dicalcium phosphate and/or a) fillers or extenders such as starches,lactose, sucrose, glucose, mannitol, and silicic acid, b) binders suchas, for example, carboxymethylcellulose, alginates, gelatin,polyvinylpyrrolidone, sucrose, and acacia, c) humectants such asglycerol, d) disintegrating agents such as agar-agar, calcium carbonate,potato or tapioca starch, alginic acid, certain silicates, and sodiumcarbonate, e) solution retarding agents such as paraffin, f) absorptionaccelerators such as quaternary ammonium compounds, g) wetting agentssuch as, for example, acetyl alcohol and glycerol monostearate, h)absorbents such as kaolin and bentonite clay, and i) lubricants such astalc, calcium stearate, magnesium stearate, solid polyethylene glycols,sodium lauryl sulfate, and mixtures thereof. In the case of capsules,tablets and pills, the dosage form can also comprise buffering agents.

Solid compositions of a similar type can also be employed as fillers insoft and hard filled gelatin capsules using such excipients as lactoseor milk sugar as well as high molecular weight polyethylene glycols andthe like.

The solid dosage forms of tablets, dragees, capsules, pills, andgranules can be prepared with coatings and shells such as entericcoatings and other coatings well known in the pharmaceutical formulatingart. They can optionally contain opacifying agents and can also be of acomposition that they release the active ingredient(s) only, orpreferentially, in a certain part of the intestinal tract, optionally,in a delayed manner. Examples of embedding compositions which can beused include polymeric substances and waxes.

The active compounds can also be in micro-encapsulated form, ifappropriate, with one or more of the above-mentioned excipients.

Liquid dosage forms for oral administration include, but are not limitedto, pharmaceutically acceptable emulsions, solutions, suspensions,syrups and elixirs. In addition to the active compounds, the liquiddosage forms can contain inert diluents commonly used in the art suchas, for example, water or other solvents, solubilizing agents andemulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate,ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol,1,3-butylene glycol, dimethyl formamide, oils (in particular,cottonseed, groundnut, corn, germ, olive, castor, and sesame oils),glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fattyacid esters of sorbitan, and mixtures thereof.

Besides inert diluents, the oral compositions can also include adjuvantssuch as wetting agents, emulsifying and suspending agents, sweetening,flavoring, and perfuming agents.

Suspensions, in addition to the active compounds, can contain suspendingagents as, for example, ethoxylated isostearyl alcohols, polyoxyethylenesorbitol and sorbitan esters, microcrystalline cellulose, aluminummetahydroxide, bentonite, agar-agar, and tragacanth, and mixturesthereof.

Alternatively, the composition can be pressurized and contain acompressed gas, such as nitrogen or a liquefied gas propellant. Theliquefied propellant medium and indeed the total composition ispreferably such that the active ingredients do not dissolve therein toany substantial extent. The pressurized composition can also contain asurface active agent. The surface active agent can be a liquid or solidnon-ionic surface active agent or can be a solid anionic surface activeagent. It is preferred to use the solid anionic surface active agent inthe form of a sodium salt.

The compositions of the present invention can also be administered inthe form of liposomes. As is known in the art, liposomes are generallyderived from phospholipids or other lipid substances. Liposomes areformed by mono- or multi-lamellar hydrated liquid crystals that aredispersed in an aqueous medium. Any non-toxic, physiologicallyacceptable and metabolizable lipid capable of forming liposomes can beused. The present compositions in liposome form can contain, in additionto the compounds of the invention, stabilizers, preservatives,excipients, and the like. The preferred lipids are the phospholipids andthe phosphatidyl cholines (lecithins), both natural and synthetic.Methods to form liposomes are known in the art (see, for example,Prescott, Ed., Meth. Cell Biol. 14:33 et seq (1976)).

One of ordinary skill in the art will appreciate that effective amountsof the agents of the invention can be determined empirically and can beemployed in pure form or, where such forms exist, in pharmaceuticallyacceptable salt, ester or prodrug form. A “therapeutically effective”amount of the inventive compositions can be determined by prevention oramelioration of adverse conditions or symptoms of diseases, injuries ordisorders being treated. The agents can be administered to a subject, inneed of treatment of viral infection, as pharmaceutical compositions incombination with one or more pharmaceutically acceptable excipients. Itwill be understood that, when administered to a human patient, the totaldaily usage of the agents or composition of the present invention willbe decided by the attending physician within the scope of sound medicaljudgement. The specific therapeutically effective dose level for anyparticular patient will depend upon a variety of factors: the type anddegree of the cellular or physiological response to be achieved;activity of the specific agent or composition employed; the specificagents or composition employed; the age, body weight, general health,sex and diet of the patient; the time of administration, route ofadministration, and rate of excretion of the agent; the duration of thetreatment; drugs used in combination or coincidental with the specificagent; and like factors well known in the medical arts. For example, itis well within the skill of the art to start doses of the agents atlevels lower than those required to achieve the desired therapeuticeffect and to gradually increase the dosages until the desired effect isachieved.

Dosing also can be arranged in a patient specific manner to provide apredetermined concentration of the agents in the blood, as determined bytechniques accepted and routine in the art. Thus patient dosaging can beadjusted to achieve regular on-going blood levels, as measured by HPLC,on the order of from 50 to 1000 ng/ml.

Various medications can lower blood cholesterol levels. Thesemedications or drugs include e.g., statins, resins and nicotinic acid(niacin), gemfibrozil and clofibrate. Clofibrate (Atromid-S) raises theHDL cholesterol levels and lowers triglyceride levels. Gemfibrozil(Lopid) lowers blood fats and raises HDL cholesterol

levels. Nicotinic Acid works in the liver and is used to lowertriglycerides and LDL cholesterol, and raise HDL (“good”) cholesterol.Resins promote increased disposal of cholesterol. Medications in thisclass include: Cholestryamine (Questran, Prevalite, Lo-Cholest);Colestipol (Colestid); and Coleseveiam (WelChol).

Statin drugs are very effective for lowering LDL (“bad”) cholesterollevels, have few immediate short-term side effects and are a preferredcholesterol lowering drug for use in the methods of the presentinvention. The statins include: Atorvastatin (Lipitor); Fluvastatin(Lescol); Lovastatin (Mevacor); Pravastatin (Pravachol); RosuvastatinCalcium (Crestor); and Simvastatin (Zocor). (See also “Cholesterollowering with statin drugs, risk of stroke, and total mortality. Anoverview of randomized trials”; Hebert P R, Gaziano J M, Chan K S,Hennekens C H. JAMA (1997) November 26; 278(20):1660-1.

HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) reductase (HMGR)catalyzes the committed step in cholesterol biosynthesis. Statins areHMGR inhibitors with inhibition constant values in the nanomolar rangethat effectively lower serum cholesterol levels and are widelyprescribed in the treatment of hypercholesterolemia. Statin drugsincrease the expression of LDL receptors on the surface of liverhepatocytes. As a consequence of the increase in LDL receptorexpression, the level of cholesterol is lowered in plasma. Thus, byadministering a statin drug, the level of competing cholesterol inplasma is reduced and the level of LDL receptors for bindingcholesterol-siRNA in the liver are increased. The invention thusprovides a method for increased uptake of cholesterol labeled siRNAwherein the siRNA is administered in conjunction with a statin wherebythe level of competing cholesterol in the serum is reduced, allowing formore efficient uptake of cholesterol labeled siRNA by hepatocytes. Thestatin can be administered before, with or after the administration ofthe cholesterol-siRNA.

It will be readily apparent to one of ordinary skill in the relevantarts that other suitable modifications and adaptations to the methodsand applications described herein can be made without departing from thescope of the invention or any embodiment thereof.

EXAMPLES

The examples demonstrate that siRNA, including modified siRNA, caneffectively inhibit viral replication in mammalian cells. Moreover, theexamples show that the inventive siRNAs promote HCV RNA degradation inhuman liver cells and establish that hepatocytes possess the necessaryfunctional components of modified siRNA-induced silencing. The examplesalso demonstrate that siRNA technology can be used as a therapy toinhibit HCV replication in host cells. The inventors, by submitting thefollowing examples, do not intend to limit the scope of the claimedinvention.

Example 1

To test whether siRNA directed to the HCV genome confers intracellularimmunity against this human pathogen, a recently developed HCV cellculture systems in human hepatoma cell line, Huh-7, was used. One of thecell lines, 5-2, harbors autonomously replicating subgenomic HCV RNA(Bartenschlager, J. Virol, 2001). The subgenomic replicon carriesfirefly luciferase gene, allowing a reporter function assay as a measureof HCV RNA replication (FIG. 5). Owing to cell culture adaptivemutations introduced into the genome (Bart), these 5-2 cells replicateHCV RNA at levels of up to 5×10⁴ virus particles/cell.

Using T7 transcription, several 21-bp siRNA duplexes against differentregions of the 5′-UTR of the HCV genome were made (FIG. 5). Briefly, 2oligo double-stranded DNA molecules comprising the T7 promoter and the5′ UTR of HCV being oriented in either the sense direction or theantisense direction were generated. Each oligo DNA was then transcribedin vitro to produce (+) and (−) RNA and then treated with DNAase I toremove the DNA template. The two RNA strands were allowed to anneal at37° C. overnight, generating dsRNA. After treating the dsRNA with RNAaseT1 to remove unreacted ssRNA species, the dsRNA was purified fortransfection.

Several other siRNA duplexes were designed, including GL2 and GL3, thatwere directed against the fruit fly and sea pansy luciferase genes,respectively. Using standard transfection techniques, the siRNAs weretransfected into the 5-2 cells and luciferase activity was measured todetermine the effect of the siRNAs on HCV replication. Luciferaseactivity was measured 48 hours after transfection. In cells where siRNA5was transfected, there was reduced luciferase activity of up to 85%, ina dose responsive manner (FIG. 6). The inhibition of luciferase activitywas not seen in cells that were transfected with irrelevant siRNA (SIN).The sequence of SIN was taken from sindbis virus transcription promoter(FIG. 1).

Example 2

The sequence specificity of the siRNA5 response was further tested usingadditional siRNA duplexes, GL2 and GL3. FIG. 1 shows that GL2 and GL3differ from each other by 3-nucleotides. Luciferase activity was reducedby 90% in cells transfected with siRNA5 or GL2, but no significantreduction was seen in cells transfected with GL3 (FIG. 7). Theluciferase assay was performed using a Luciferase assay system availablefrom Promega Corp. (Madison, Wis.), according to the manufacturer'sinstructions.

Example 3

Whether or not siRNA5 was toxic to transfected cells also was tested.Toxicity was by measured using an ATPase activity assay. FIG. 8 showsthat the siRNA5-induced reduction in HCV replication, as seen in FIG. 6,was not due to cellular toxicity which is attributed to nonsequence-specific RNAi. ATPase levels were assayed using an ATPase assaykit from Promega (Madison, Wis.) according to the manufacturer'sinstructions.

Example 4

The full-length HCV replicon may possess the ability to adapt andsuppress RNAi, thus replicating in spite of the presence of siRNA, asdocumented in Li, H, Science 296:1319-1321 (2002). To determine theeffects of siRNA5 on replication of full-length HCV RNA in Huh-7 cells,from the 21-5 cell line, harboring the selectable full-length HCVreplicon, were treated with siRNA5. Levels of HCV RNA were measured byquantitative PCR using TaqMan™ (F. Hoffman La-Roche, Switzerland). Theresults as seen in FIG. 9 show that siRNA-directed silencing reducedsteady-state viral RNA production, even in the setting of an adapted HCVmutant, where RNA replication was very high. Results from bothsubgenomic and full-length HCV replicons suggest that none of the HCVproteins can suppress RNA interference.

Example 5

Whether or not siRNA5 was toxic to transfected cells also was tested.Specifically, mRNA encoding GAPDH, an enzyme essential in glycolysis,was measured in Huh 5-2 cells transfected with siRNA5, or siRNA specifictowards the GAPDH sequence. FIG. 10 demonstrates that siRNA5 did notaffect RNA levels of GAPDH. GAPDH was measured using a TaqMan™ RNA kit(F. Hoffman La-Roche, Switzerland) according to the manufacturer'sinstructions.

Example 6

To test the effectiveness of siRNA5 on inhibiting the ability of HCV toreplicate in an infected liver, portions of HCV-infected human liver arexenografted onto transgenic severe combined immunodeficient (SCID) miceaccording to methods well known to the skilled artisan.

Briefly, once the HCV-infected liver has supplanted the mouse liver,liposome-encapsulated siRNA5, or control liposomes are administered byintravenous injection to the mice through the tail vein, or anotheraccessible vein. The mice are dosed one time a day for 3-10 days.

At the end of the dosing regimen the mice are sacrificed and bloodcollected and the livers removed. The liver is divided into portionssuch that a portion is frozen using liquid nitrogen, a portion is fixedfor paraffin embedding, and a portion is fixed for sectioning ontoslides.

Using the appropriate allotment, HCV RNA is quantified using the TaqMan™RNA assay kit previously utilized herein to determine the levels of HCVRNA in the liver cells. Further, anti-HCV antibody titers can bemeasured in the collected blood samples, along with serum ALT levels.

Example 7

To test the effectiveness of siRNA5 on inhibiting the ability of HCV toinfect a healthy liver, portions of normal human liver are xenograftedonto transgenic severe combined immunodeficient (SCID) mice according tomethods well known to the skilled artisan.

Briefly, once the healthy liver has supplanted the mouse liver,liposome-encapsulated siRNA5, or control liposomes are administered byintravenous injection to the mice through the tail vein, or anotheraccessible vein. The mice are dosed one time a day for 3-10 days. Afterthe pre-dosing regimen, active HCV is then injected intravenously, orvia hepatic injection, into the mice.

At about 6, 12, 18, 24 hours, and periodically up to about 5 days afterthe mice are infected with HCV, the mice are sacrificed and bloodcollected and the livers removed. The liver is divided into portionssuch that a portion is frozen using liquid nitrogen, a portion is fixedfor paraffin embedding, and a portion is fixed for sectioning ontoslides.

Using the appropriate allotment, HCV RNA is quantified using the TaqMan™RNA assay kit previously utilized herein to determine the levels of HCVRNA in the liver cells. Further, anti-HCV antibody titers can bemeasured in the collected blood samples, along with serum ALT levels.

Example 8

Modified siRNA can be prepared by chemical synthesis. In one embodiment,each C and U within a siRNA duplex, e.g. GL2, can be substituted with2′-F-U and 2′F-C. To produce siRNA with 3′-end overhangs comprising2′-F-U and 2′F-C, a universal support can be used. By selectivelycleaving the oligo from the support, a practitioner can ensure thatresidues of the overhangs comprise modified nucleotides. Alternatively,the nucleotides comprising the 3′-end overhang can be unmodified dTdT.

2′-F RNA oligonucleotides can be synthesized on an Applied Biosystems8909 or 8905 DNA/RNA synthesizer using the standard 1 μmolbeta-cyanoethyl phosphoramidite RNA chemistry protocol. The RNAphosphoramidite monomers and columns of Pac-A, 2′-F-Ac-C, iPr-Pac-G,2′-F-U, and U-RNA CPG can be obtained from Glen Research (Sterling,Va.). (See catalog nos. 10-3000-05, 10-3415-02, 10-3021-05, 10-3430-02,and 20-3430-41E, respectively.) Glen Research's Sulfurizing Reagent(catalog no. 40-4036-10) can be used as an oxidant to obtain a singlephosphorothioate backbone between the 3′ CPG and a subsequent base. Toattain the coupling, the oxidizing step of the standard RNA 1 μmolprotocol can be replaced with the standard thioate 1 μmol protocol.Cholesteryl-TEG phosphoramidite (Glen Research, catalog no. 10-1975-90)and cholestryl-TEG CPG (Glen Research, catalog no. 20-2975-41E) can beincorporated onto the 5′ or 3′ ends of one or more of theoliogoribonucleotides. After synthesis, the 2′-F RNA's are cleaved anddeprotected with 1:1 ammonium hydroxide/methylamine, and the silylgroups are removed with triethylamine trihydrofluoride using standardprotocols. See e.g.http://www.glenres.com/productfiles/technical/tb_rnadeprotection.pdf.The oligoribonucleotides are then desalted on Sephadex G25 columns(Pharmacia NAP 25, catalog no. 17-08252-02) with sterilized water andpurified using standard gel electrophoresis protocols. Modified siRNAsalso can be obtained from commercial vendors such as Dharmacon(Lafayette, Colo.).

Alternatively, modified siRNA can be prepared by transcription using theDurascribe™ T7 Transcription Kit purchased from Epicentre Technologies(Madison, Wis.).

The modified siRNAs (dsRNAs) made by these methods containphosphodiester linked oligonucleotides. Standard methods for makingmodified single-stranded RNAs, such as antisense molecules, are usefulfor making modified siRNAs, as modified single-stranded RNAs can beannealed together to form double stranded RNAs. Such standard methodsinclude, but are not limited to, those described in Chiang et al., J.Biol. Chem. 266, 18162-18171 (1991); Baker et al., J. Biol. Chem. 272,11994-12000 (1997); Kawasaki et al., J. Med. Chem. 36, 831-841 (1993);Monia et al., J. Biol. Chem. 268, 14514-14522 (1993).

Example 9

To test whether siRNA directed to the HCV genome confers intracellularimmunity against this human pathogen, a recently developed HCV cellculture systems in human hepatoma cell line, Huh-7, was used. One of thecell lines, 5-2, harbors autonomously replicating subgenomic HCV RNA(Bartenschlager, J. Virol, 2001). The subgenomic replicon carriesfirefly luciferase gene, allowing a reporter function assay as a measureof HCV RNA replication. Owing to cell culture adaptive mutationsintroduced into the genome, 5-2 cells replicate HCV RNA at levels of upto 5×10⁴ virus particles/cell.

Using T7 transcription, several 21-bp siRNA duplexes against differentregions of the 5′-UTR of the HCV genome were made. Briefly, two oligodouble-stranded DNA molecules comprising the T7 promoter and the 5′ UTRof HCV being oriented in either the sense direction or the antisensedirection were generated. Each oligo DNA was then transcribed in vitroto produce (+) and (−) RNA and then treated with DNAase I to remove theDNA template. The two RNA strands were allowed to anneal at 37° C.overnight, generating dsRNA. After treating the dsRNA with RNAase T1 toremove the unreacted ssRNA species, the dsRNA was purified fortransfection.

Two exemplary modified siRNAs are provided below (SEQ ID NOS 5 and 6):

Chol-GL2 Chol- CGUACGCGGAAUACUUCGAUU UUGCAUGCGCCUUAUGAAGCU GL2CGUACGCGGAAUACUUCGAUU UUGCAUGCGCCUUAUGAAGCU

Each C and U within siRNA GL2, directed against the fruit fly luciferasegene, was substituted with 2′-F-U and 2′F-C. The modified siRNAs weretransfected into the 5-2 cells using standard liposome transfectiontechniques. Specifically, the modified siRNAs were incubated for 4 hrsat 37° C. in a 250 μl cell suspension containing 0.5 μl ofOligofectamine (Invitrogen, Carlsbad, Calif.), for 20 hrs in 375 μlserum containing culture medium, and for 24 hrs at 37° C. in freshmedium without the liposome-siRNA complex. Luciferase activity wasmeasured 48 hours after transfection to determine the effect of themodified siRNAs on HCV replication.

FIG. 11 shows that GL2 reduced the luciferase activity at increasingconcentrations. Luciferase activity was reduced by 90% in cellstransfected with 2′-F-GL2, but no significant reduction was seen inmocked transfected cells or with a control (2′-F-GFP=green fluorescentprotein). The luciferase assay was carried out using a Luciferase assaysystem available from Promega Corp. (Madison, Wis.), according to themanufacturer's instructions.

The siRNA Chol-GL2 comprises a cholesteryl group on one of the 5′ ends.5-2 cells were incubated with various concentrations of Chol-GL2 in theabsence of liposomes. Cells were harvested 48 hours after incubation andassayed for luciferase activity. FIG. 12 shows that Chol-GL2 inhibitedluciferase gene activity in a dose-dependent manner. InvA refers tochol-GL2 in inverted sequence.

Example 10

To test the stability of 2′ chemically modified siRNA compared tounmodified siRNA (siRNA), the following experiment is performed. Fournanograms of siRNA are added to a 20 μL volume of 80% human serum from ahealthy donor. This mixture is incubated at 37 C.° for various timesranging from 1 minute up to 10 days. The results are depicted in lanes2-10 of FIG. 13. The same process is performed for 2′ fluorine modifiedsiRNA (2′-F siRNA) as well and the results are shown in lanes 12-20 and22-25 of FIG. 3. When the incubation process is finished, the mixturesare placed on ice and then immediately separated by PAGE along with a³²P-siRNA control (See Lanes 1, 11 and 21 of FIG. 13). The data showthat the 2′-modified siRNA is stable over a period of 10 days ascompared to unmodified siRNA.

Example 11

To demonstrate the production of modified siRNA from long dsRNA, fivemicrograms of 1000 bp-long fluorinated dsRNAs (FIG. 14, panel (A)) wereincubated overnight with 15 units of human Dicer at 37° C. The resultingdiced-siRNAs were purified using a Sephadex G-25 column andelectrophoresed on 20% PAGE (FIG. 14, panel (B)). FIG. 4 shows thatrecombinant human dicer effectively converts fluorinated-dsRNA into2′F-siRNA.

Example 12

To further test whether siRNAs directed to the HCV genome conferintracellular immunity against this human pathogen, the assay describedin Example 1 was employed to test siRNAC1, siRNAC2, siRNA5B1, siRNA5B2,and siRNA5B4, each of which is shown in FIG. 2. Each siRNA was tested atconcentrations of 1 nM, 10 nM and 100 nM. As shown in FIG. 15, each ofthe siRNAs significantly inhibited luciferase activity in adose-dependent manner. SiRNAC2 exhibited particular effectiveness.

Example 13

As a follow-up to the experiments reported in Example 9, assays wereperformed to demonstrate that the cholesterol modification, and not thefluoro modification directed siRNA molecules to Huh-7 liver cells. Huh-7cells were incubated with various concentrations of two kinds ofChol-GL2 siRNAs: one having a 2′-fluoro modification and the otherlacking such a modification. The results, shown in FIG. 16 demonstratethat the deliver of cholesterol-modified siRNA molecules to liver cellsis due to the cholesterol, and not other modifications.

Example 14

siRNA was modified to include 2-Fluoro pyrimidines in place of all ofthe pyrimidines (2′-F-siRNA). This 2′-F-siRNA was further modified toinclude a two base deoxynucleotide “TT” sequence added to the 3′ends ofthe molecule in place of the ribonucleotide “UU” overhangs present in2-F-siRNA (2′-F-siRNA 3′-X). FIG. 17 demonstrates that the furthermodification of the 2′ fluorinated siRNA to include a 3′“dTdT” terminusresulted in significant increase in stability of the siRNA in humanserum.

1. A method for inhibiting Hepatitis B Virus (HBV) replication in apatient, the method comprising the steps of: (a) administering to saidpatient a composition comprising a modified double-stranded RNA (dsRNA)or modified small interfering RNA (siRNA) in an amount effective tomediate RNA interference and to inhibit HBV replication, wherein themodified dsRNA or modified siRNA comprises a first strand and a secondstrand, wherein the first and second strand are each no more than about30 ribonucleotides in length and wherein the first or second strandtargets HBV; and wherein the modified dsRNA or modified siRNA ischolesterol-labeled, and (b) administering to said patient acholesterol-lowering drug, wherein steps (a) and (b) can be performedsimultaneously or in any order, and (c) wherein the cholesterol-loweringdrug reduces the level of competing cholesterol in the serum, allowingmore efficient uptake of the cholesterol-labeled modified dsRNA ormodified siRNA by hepatocytes.
 2. The method of claim 1, wherein saidcholesterol-lowering drug is a statin, resin, nicotinic acid,gemfibrozil or clofibrate.
 3. The method of claim 1, wherein saidcholesterol-lowering drug is a statin.
 4. A method for inhibitingHepatitis B Virus (HBV) replication in a patient, the method comprisingthe steps of: (a) administering to said patient a composition comprisinga modified double-stranded RNA (dsRNA) or modified small interfering RNA(siRNA) in an amount effective to mediate RNA interference and toinhibit HBV replication, wherein the modified dsRNA or modified siRNAcomprises a first strand and a second strand, wherein the first andsecond strand are each no more than about 30 ribonucleotides in lengthand wherein the first or second strand targets HBV; and wherein themodified dsRNA or modified siRNA is cholesterol-labeled, and (b)administering to said patient a cholesterol-lowering drug, wherein steps(a) and (b) are performed simultaneously, and (c) wherein thecholesterol-lowering drug reduces the level of competing cholesterol inthe serum, allowing more efficient uptake of the cholesterol-labeledmodified dsRNA or modified siRNA by hepatocytes.
 5. The method of claim4, wherein said cholesterol-lowering drug is a statin, resin, nicotinicacid, gemfibrozil or clofibrate.
 6. The method of claim 4, wherein saidcholesterol-lowering drug is a statin.